The serum osteocalcin levels in patients with thyroid diseases

Area of Science:

• Endocrinology
• Bone Metabolism
• Thyroid Disease

Background:

• Bone, calcium, phosphorus, and protein abnormalities in hyperthyroidism are complex and not fully understood.
• Elevated serum osteocalcin has been observed in hyperthyroid patients, decreasing after treatment.
• Osteocalcin is a marker of bone turnover, reflecting bone formation and resorption processes.

Purpose of the Study:

• To measure serum osteocalcin levels in patients with various thyroid diseases.
• To investigate the relationship between thyroid disease, osteocalcin levels, and treatment status.
• To analyze the persistence of bone resorption markers despite anti-thyroid therapy.

Main Methods:

• Serum osteocalcin was measured using radioimmunoassay (RIA).
• 229 patients (211 women, 18 men) with thyroid diseases were studied.
• Patients were categorized into groups: goiter/thyroiditis, Graves' disease, and thyroid cancer (post-treatment).

Main Results:

• Significantly elevated osteocalcin levels were found in Graves' disease patients (16.31 ng/ml women, 12.75 ng/ml men) compared to goiter/thyroiditis (2.97 ng/ml women, 3.56 ng/ml men) and thyroid cancer (1.01 ng/ml women, 0.78 ng/ml men) groups.
• No significant difference in osteocalcin levels was observed between treated and untreated hyperthyroid women.
• Osteocalcin levels remained high in hyperthyroid patients, indicating persistent bone resorption.

Conclusions:

• Bone resorption stimulated by thyroid hormones is a resistant process, persisting even after 6-8 months of anti-thyroid therapy.
• Subnormal osteocalcin levels in treated thyroid cancer patients warrant further investigation into suppression therapy effects.
• Osteocalcin measurements provide insights into bone turnover dynamics in different thyroid conditions.